GARDASIL, on the other hand, is said to use an amorphous aluminium hydroxyphosphate sulphate adjuvant. It notes that the GSKA Information Sheet states that CERVARIX is the only vaccine to have shown evidence of additional cervical cancer coverage due to protection against two other cancer-causing HPV type infections (HPV 31 and 45). 73 Mr Herd also challenged Dr Anderson's claims regarding the harm that CSL might suffer with regard to CSL's application for public funding of GARDASIL on the National Immunisation Program ("the NIP"). That representation, CSL contends, was false. GSKA had refused to do so.